Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib

Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical r...

Full description

Bibliographic Details
Main Authors:	Vyas, P, Quek, L, David, MD, Kennedy, A, Metzner, M, Amatangelo, M, Shih, A, Stoilova, B, Quivoron, C, Heiblig, M, Willekens, C, Saada, V, Alsafadi, S, Vijayabaskar, MS, Peniket, A, Bernard, OA, Agresta, S, Yen, K, MacBeth, K, Stein, E, Vassiliou, GS, Levine, R, De Botton, S, Thakurta, A, Penard-Lacronique, V
Format:	Journal article
Published:	Springer Nature 2018

Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib

Similar Items